FRANKFURT, Oct 10 (Reuters) - Merck KGaA's Rebif multiple-sclerosis drug is not superior to rival Teva's Copaxone, a study obtained by Reuters on Wednesday showed. "The number of events (relapses) was ...

An estimated 2.5 million people suffer from multiple sclerosis (MS) worldwide—less than 0.04% of the global population. However, the epidemiology of the disease appears to be undergoing dramatic ...

CAMBRIDGE, MA – Sept. 11, 2009 – Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon ...

FRANKFURT, Oct 10 (Reuters) - Shares in German chemicals and drugs group Merck KGaA fell as much as 2.7 percent on Wednesday after a surprise management reshuffle at its lucrative liquid crystals unit ...

“We believe that a head-to-head trial is necessary to provide scientific data that can be used to compare different therapeutic options,” said Serono’s chief medical officer, Paul Lammers. “We expect ...

Rebif (interferon beta-1a) is a prescription drug used to treat types of multiple sclerosis. Rebif can cause side effects that range from mild to serious. Examples ...

Merck, a leading science and technology company, today announced that data for approved and investigational multiple sclerosis (MS) treatments, MAVENCLAD ® (Cladribine Tablets) and Rebif ® (interferon ...

Multiple sclerosis—so named because the disease results in multiple scars (or scleroses) on the myelin sheath, which surrounds the body's neurons—affects the body's central nervous system. Symptoms ...

Rebif (interferon beta-1a) is a prescription drug used to treat some types of multiple sclerosis (MS). Rebif may be safe to use while pregnant or breastfeeding. Keep ...

Rebif is a brand-name liquid solution that’s typically self-injected. It’s prescribed for certain forms of multiple sclerosis (MS) and contains the active ingredient interferon beta-1a. It is not ...